Compare Citius Pharmaceuticals Inc (CTXR) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nasdaq Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Nasdaq Inc trades at $95.92 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 2654.2× Citius Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NDAQ | |
|---|---|---|
Market Cap | $20.01M | $53.11B |
Sector | Health | Financials |
52-Week High | $1.82 | $100.98 |
52-Week Low | $0.48 | $76.85 |
Enterprise Value | $16.23M | $59.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Nasdaq (NDAQ) trades at $95.26, down 0.38% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $8.26B in 2025, with net income reaching $1.79B and a profit margin of 21.64%. The company has beaten EPS estimates in recent quarters and announced the acquisition of LeveL Markets to expand its market infrastructure. Analyst consensus is strongly positive, with a $109.20 price target indicating ~15% upside.
Outlook remains favorable driven by earnings growth and strategic acquisitions, though risks include market volatility and integration challenges. The stock offers value through consistent profitability and dividend payments, supported by institutional confidence. Investors should weigh execution risks against the potential for continued expansion in financial services technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
